OptimizeRx Reiterates FY24 Guidance With Revenue To Be At Least $100M (Est $101.313M), Adjusted EBITDA Of At Least $11M
Portfolio Pulse from Benzinga Newsdesk
OptimizeRx has reiterated its FY24 guidance, projecting revenues of at least $100M, slightly below the estimated $101.313M, and an adjusted EBITDA of at least $11M.
May 14, 2024 | 8:29 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
OptimizeRx reiterates its FY24 guidance with expected revenues of at least $100M, against an estimate of $101.313M, and an adjusted EBITDA of at least $11M.
Reiterating guidance typically stabilizes investor confidence, indicating management's belief in meeting targets. The slight discrepancy between projected and estimated revenues may not significantly impact investor sentiment, as the focus is on meeting the broader financial goals.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100